Biotech News
Related news
TSHATaysha Gene Therapies2026-08-03 12:00 EST
Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome
OCGNOcugen2026-07-13 11:02 EST
Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa
MXCTMaxCyte2026-06-23 13:00 EST
VectorBuilder Partners with MaxCyte® to Advance Clinical-Grade Cell Engineering
SANASana Biotechnology2026-04-13 20:05 EST
Sana Biotechnology and Mayo Clinic Announce Strategic Collaboration Focused on Improving Care in Type 1 Diabetes and Accelerating Development of SC451
MXCTMaxCyte2026-07-15 20:05 EST
MaxCyte to Report Second Quarter 2026 Financial Results on August 12, 2026
GSKGSK plc2026-05-11 12:00 EST
GSK enters exclusive collaboration with SBP Group, a market leader in hepatology in China, to accelerate bepirovirsen at launch
SGMOSangamo Therapeutics, Inc.2026-04-30 12:05 EST
Sangamo Therapeutics to Present Pipeline and Technology Advances at the 29th Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT)
CRBUCaribou2026-06-29 12:00 EST
Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
SANASana Biotechnology2026-05-12 20:05 EST
Sana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell Depletion in NHPs
ABEOAbeona Therapeutics2026-08-04 11:30 EST
CMS Grants New Technology Add-On Payment (NTAP) Status for ZEVASKYN®
MaxCyte
Cell Engineering Platform MaxCyte provides electroporation systems and services used to engineer cells for research, clinical development, and commercial cell therapies. ExPERT Platform The ExPERT instruments introduce molecules into cells at laboratory through commercial scale while preserving cell viability and function. Strategic...
Recent company news
MXCTMaxCyte2026-07-21 12:05 EST
MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development
MXCTMaxCyte2026-07-15 20:05 EST
MaxCyte to Report Second Quarter 2026 Financial Results on August 12, 2026
MXCTMaxCyte2026-06-23 13:00 EST
VectorBuilder Partners with MaxCyte® to Advance Clinical-Grade Cell Engineering
MXCTMaxCyte2026-05-12 20:06 EST
MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance
MXCTMaxCyte2026-04-29 20:05 EST
MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026
Stock data
- Close
- 1.11 USD
- Market cap
- 131.76M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States